

## ASX Announcement

# Clarification – 5-fold Increase to Concentration of RECCE<sup>®</sup> 327 in Urine and Plasma

**SYDNEY Australia, 20 July 2023:** Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) (the **Company**), the Company developing a new class of Synthetic Anti-infectives, wishes to clarify the announcement released on 19 July 2023 surrounding the Complete Data Review.

That announcement potentially understated the Urine and Plasma concentration of RECCE<sup>®</sup> 327 (R327), as the table under the heading “Positive Unexpected Findings” reported on only one oligomer (being, Oligomer 5, which is of specific importance) as part of the suite of oligomers that make the total R327 polymer.

Accounting for all relevant oligomers, consistently with Recce’s previous reporting of Urine and Plasma concentrations, the updated figures are approximately **5-fold higher** than what was announced on 19 July 2023.

The new concentration data points, reflecting total R327, is as follows:

R327 dose (mg)	C <sub>MAX</sub> Plasma (ug/ml)	C <sub>MAX</sub> Urine (ug/ml)	Ratio - urine/plasma
500	<b>15.792</b>	<b>251.45</b>	<b>16x</b>
1,000	<b>31.584</b>	<b>520.76</b>	<b>17x</b>
2,000	<b>60.63</b>	<b>827.67</b>	<b>14x</b>
3,000	<b>86.01</b>	<b>738.84</b>	<b>9x</b>
4,000	<b>111.86</b>	<b>2304.88</b>	<b>21x</b>
6,000	<b>171.55</b>	<b>2682.76</b>	<b>16x</b>

This announcement has been approved for release by Recce Pharmaceuticals Board.



**ASX: RCE, FSE: R9Q**

**Head Office:** Level 23, 180 George St, Salesforce Tower, SYDNEY NSW 2000 **T** +61 (02) 9256 2505

**R&D Centre - Perth:** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

**Washington Office:** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA